Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MR1-restricted T cells: the new dawn of cancer immunotherapy.

Bioscience reports - 27 Nov 2020

Wang Zhiding, Wang Mengzhen, Chen Jinghong, Zhang Linlin, Zhang Li, Yu Li

Abstract excerpt

Cancer immunotherapy has recently undergone rapid development into a validated therapy for clinical use. The adoptive transfer of engineered autologous T cells, such as chimeric antigen receptor (CAR) T cells, has been remarkably successful in patients with leukemia and lymphoma with cluster of differentiation (CD)19 expression. Because of the higher number of antigen choices and reduced incidence of cytokine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histocompatibility Antigens Class I
Share to Immunotherapy, Adoptive
Share to Lymphocytes, Tumor-Infiltrating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Minor Histocompatibility Antigens

Share to Neoplasms

Share to Phenotype

Share to Prognosis

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 33185693
DOI: 10.1042/BSR20202962
PMCID: PMC7670570

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MR1-restricted T cells: the new dawn of cancer immunotherapy.PMID 33185693Read ↗

MR1-Restricted T Cells Are Unprecedented Cancer Fighters.Semantic proximity Read ↗

Conserved allomorphs of MR1 drive the specificity of MR1-restricted TCRsSemantic proximity Read ↗

The Conventional Nature of Non-MHC-Restricted T CellsSemantic proximity Read ↗

Characterization of Tumor-Infiltrating Lymphocyte-Derived Atypical TCRs Recognizing Breast Cancer in an MR1-Dependent Manner.Semantic proximity Read ↗

Engineering human Mucosal Associated Invariant T (MAIT) cells with chimeric antigen receptors for cancer immunotherapy <sup>1</sup>Semantic proximity Read ↗

Antigen Recognition by MR1-Reactive T Cells; MAIT Cells, Metabolites, and Remaining Mysteries.Semantic proximity Read ↗

Conserved allomorphs of MR1 drive specificity of MR1-restricted TCRsSemantic proximity Read ↗

Chimeric Antigen Receptors: A Paradigm Shift in ImmunotherapySemantic proximity Read ↗

Engineering of Isogenic Cells Deficient for MR1 with a CRISPR/Cas9 Lentiviral System: Tools To Study Microbial Antigen Processing and Presentation to Human MR1-Restricted T CellsSemantic proximity Read ↗

CAR-T-Cell Therapy: Present Progress and Future strategiesSemantic proximity Read ↗

The Advance Cancer Immunotherapy Techniques and the Future Perspective of Modified T Cell TherapySemantic proximity Read ↗

PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.